Company intelligence / Profile preview

Human Immunology Biosciences

South San Francisco, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Felzartamab demonstrated positive interim results from Phase 2 IgA nephropathy study and completed Phase 2 antibody-mediated rejection study. The AMR study data were published in the New England Journal of Medicine. Felzartamab also demonstrated proof-of-concept in a Phase 2 study in primary membranous nephropathy, with plans to advance to Phase 3 in AMR, IgAN, and PMN.[9]

Therapeutic areas: ImmunologyNephrology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

felzartamab

Phase 2

Indications: IgA nephropathy, Membranous nephropathy, Antibody-mediated rejection

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Human Immunology Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human Immunology Biosciences.

Explore the full profile